Aion Therapeutic Combines the Healing Powers of Cannabinoids and Psychedelics to Treat Cancer and Depression

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

To date, 74% of prescription drugs are derived from plants, 18% specifically from fungi. Still, many companies hesitate to invest in the medicinal benefits of mushrooms.

International pharmaceutical company Aion Therapeutic Inc. AION is taking the use of psychedelic mushrooms to the next level by combining them with cannabinoids. While some might call this a bold endeavor, evidence that these plants hold special healing properties has been present for centuries.

Cannabis and Psychedelics as Medicine

Numerous cultures and societies including the Egyptians, Aztecs, Vikings, Greeks and Romans have used cannabis and mushroom plants for their natural healing powers. As far as history reveals, human use of these plants dates back to Neolithic human history.

Today, Aion Therapeutic seeks to move these practices forward by specializing in joining mushroom and cannabis compounds to create a new class of therapeutics to treat cancer, depression, viral infections, inflammation and other indications.

Mushrooms and cannabis have grown symbiotically in nature for millions of years, assisting in one another’s growth. Mushrooms help cannabis plants to absorb nutrients, while cannabis assists mushrooms in acquiring carbohydrates. With 2 plants already working together naturally, why not encourage their relationship further with pharmaceutical development?

Aion is doing just that and has been focusing much of its resources on the treatment of cancer and depression, arguably 2 of society's most common and challenging ailments.

Harnessing Nature’s Gifts Safely and Legally

Recently, the U.S. Food and Drug Administration (FDA) designated psilocybin as a "breakthrough therapy" for the treatment of major depressive disorder (MDD). But with strict regulations still in place worldwide for both cannabis and psychedelic mushroom plants, Aion Therapeutic had to get creative about finding an appropriate location for its research and development facilities.

In Jamaica, medicinal mushrooms, including those containing psilocybin, have always been legal, and medical cannabis is federally legal and regulated. This legislative power makes it one of the only places where it’s legal to operate and create medical products that include both psilocybin and THC.

In this fully federally legal environment, Aion works in partnership with a Jamaican medical cannabis licensed partner to perform combitorial research and development, treat patients and commercialize its product lines.

Positive Results and Upcoming Developments

In April 2021, the company announced that its proprietary and patented combinatorial mushroom preparations, AION F7 and AION F8, showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells and triple-negative breast cancer cells by direct cytotoxicity (i.e., chemotherapy).

Aion Therapeutic is in the process of bringing its research findings into clinical trials as well as beginning commercial production of nutraceuticals and cosmeceuticals.

On July 15-16, 2021, at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, Dr. De La Haye, medical director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), announced the opening of Aion’s International Center for Psychedelic Psychiatry in Kingston, Jamaica.

The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol and other drug misuse), treatment-resistant depression and anxiety associated with life-threatening illnesses. In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD) and anorexia nervosa.

Trusted Shareholders, Experienced Team

Aion Therapeutic CEO Graham Simmonds is also the chair of Plant-Based Investment Corp., PBIC currently Aion’s largest cash investor.

“Plant-Based Investment Corp. is committed to the success and progress of Aion Therapeutic. The company has the utmost confidence in the team’s expertise, strategic planning and robust IP portfolio,” commented Simmonds.

Visit https://www.aiontherapeutic.com/ for more information.

Aion Therapeutic is a partner of Benzinga. The information in this article does not represent the investment advice of Benzinga or its writers.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.